Hope For Alzheimer's patients
and Caregivers
An exciting new clinical trial is evaluating an
investigational treatment for agitation in Alzheimer's
What Are The Symptoms of Agitation?
Physical aggression:
e.g., hitting, kicking, biting.
Pacing or aimless wandering:
Repetitive actions or movements (e.g., tapping, fidgeting, rocking).
Verbal outbursts or aggression:
e.g., yelling, cursing, whining.
Destructive behavior:
e.g., earing objects, throwing things, hoarding.
Excessive demands for attention or help.
Restlessness or inability to stay still
What is Agitation in Alzheimer's?
CALMA is a multicenter Phase 2 clinical trial designed to evaluate the safety and efficacy of IGC-AD1 for treating agitation associated with Alzheimer’s dementia.
FDA Registered Trial
Clinical Trial Identifier: NCT 05543681
Clinicaltrials.gov:
https://clinicaltrials.gov/study/NCT05543681
Diagnosis of Alzheimer’s Disease.
Symptoms of agitation, aggression, irritability, or restlessness.
Regular behavioral medications are permitted before and during the study.
Have a caregiver who maintains daily contact with the study participant and commits to complying with the study procedures.
- No cost to participate in the CALMA trial
- We cover your expenses*
- Minimal time commitment- Only three clinic visits
- Receive a blood pressure monitor and weighing scale at no cost
- A dedicated care team supporting you every step of the way
Take part in groundbreaking research while receiving expert support
- Up to $500
- Assess the efficacy of IGC-AD1 on cognition at Week 6.
- Measure changes in caregiver burden.
- Safety and Tolerability
- Analyze the biomarker panel.
- Daily Logbook with vitals.
In Clinic
Three visits
Safety Calls
Daily for the first three days. Afterwards every third day to review safety and compliance.
Please expect an email from our team, we will reach out to you shortly.
📩 Have questions? Contact us at calma@igcpharma.com
